Carboplatin: 338 Real Stories

338 stories match carboplatin. 332 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

ALK-positive lung cancer spreading to both breasts after years of targeted therapy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: ALK-positive, ALK mutation

Metastatic Site: bilateral breasts

At age 51, about 10 years after his Stage IV diagnosis, he remained alive with stable disease 8 months after removal of bilateral breast metastases while continuing maintenance therapy.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Primary Lung Cancer That Spread to Both Breasts and the Adrenal Gland

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 negative; EGFR, ALK, ROS1, RET, MET exon 14, NTRK and BRAF wild type

Metastatic Site: both breasts, subcutaneous tissue, adrenal gland

After the lung origin was established, she was in good general condition and asymptomatic while first-line systemic therapy was being planned.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer: response to carboplatin, etoposide, and atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CD56-positive; synaptophysin-positive

Metastatic Site: right hilar/mediastinal disease, left adrenal gland,…

Extensive-stage small-cell lung cancer presenting with chronic intestinal pseudo-obstruction improved after 3 cycles of carboplatin, etoposide, and atezolizumab, with PET response and symptomatic improvement; longer-term durability was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 lung cancer: immunotherapy plus particle therapy halts progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 90%; high tumor mutational burden; PIK3CA ; TP53 mutation; MET mutation

Metastatic Site: left proximal femur

Stage IV oligometastatic NSCLC had good CT response to carboplatin, pemetrexed, and pembrolizumab, then no disease progression 6 months after PULSAR radiotherapy plus pembrolizumab; grade 2 pneumonitis improved with prednisone.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Triple-Negative Pleomorphic Lobular Breast Cancer in a BRCA1 Carrier

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative, BRCA1 pathogenic mutation

Surgery after neoadjuvant treatment showed a complete pathologic response with no cancer in the 2 sampled sentinel lymph nodes.

PubMed Central
OutcomeResponding Well
Att, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Att's Patient Story

Patient Info: Att Callahan, Female, 70+ | Stage II

As of July 2024, Att was receiving monthly post-surgery immunotherapy and scans every other month after clinical-trial chemoimmunotherapy and lobectomy, with doctors believing they had removed all visible cancer.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Stage 4 lung cancer: complete response to chemo-immunotherapy combo

Patient Info: Anonymized, Male, 40s | Stage IV

Metastatic Site: right hilar lymph nodes, mediastinal lymph nodes

Stage IVA lung squamous cell carcinoma achieved complete response at 12 months. Pembrolizumab was stopped after immune-related RS3PE and likely colitis; 8 months after glucocorticoid initiation, there was no relapse of lung cancer or RS3PE.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Near-complete response to osimertinib in Stage IV lung adenocarcinoma with rare EGFR mutations

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR S768I mutation, PD-L1 TPS 2%

Metastatic Site: pleura, bone, lymph nodes

After progression on vinorelbine and carboplatin, osimertinib produced a metabolic complete response by December 2023 and a near-complete radiologic response in March 2024. He remained on osimertinib with good tolerance and stable clinical condition.

PubMed Central
OutcomeResponding Well
Lenny, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV Non-Small Cell Lung Cancer: Lenny's Survivor Story

Patient Info: Lenny, Male, 50s | Stage IV

Biomarkers: PD-L1 expression positive

Metastatic Site: right femur; brain/cerebellum

As of July 2024, Lenny described himself as NED/no evidence of disease after surgery, CyberKnife radiation, chemotherapy, and Keytruda-based immunotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Five-year survival with extensive-stage small cell lung cancer on atezolizumab

Patient Info: Anonymized, Male, 50s | Stage IV

Metastatic Site: bilateral lungs, cervical lymph nodes

Five years after diagnosis with extensive-stage small cell lung cancer, he was alive and well on maintenance atezolizumab with no further documented progression after the 2020–2021 rechallenge, reaching 60 months overall survival and about 44 months progression-free survival.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IVA lung adenocarcinoma with solitary brain metastasis: pCR after brain surgery, chemoradiation, immunotherapy, and lobectomy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 75%; negative for driver gene mutations and translocations

Metastatic Site: brain

As of May 2024, he had no recurrence after brain metastasis resection and radiation, carboplatin/pemetrexed/atezolizumab, robot-assisted right upper lobectomy with pathologic complete response, and 13 cycles of maintenance atezolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage 2 triple-negative breast cancer: pathologic complete response to chemotherapy

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: Triple-negative breast cancer, with pathogenic PALB2 c.1451T>A variant found in blood/buccal/tumor testing.

As of May 2024, more than 1 year after surgery, she was well and free of cancer after neoadjuvant chemotherapy, mastectomy, reconstruction, and preventive adnexectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung adenocarcinoma: complete response on immunotherapy combination

Patient Info: Anonymized, Male | Stage IV

Biomarkers: No targetable mutation found. Tissue showed TP53/ARID1A; liquid biopsy added KEAP1, and SMARCA4. PD-L1 not evaluable.

Metastatic Site: bilateral lung nodules, left adrenal gland

As of May 2024, metastatic lung adenocarcinoma had a complete radiologic response lasting more than 14 months on pembrolizumab maintenance, and a new PET-avid lung nodule was benign inflammation rather than cancer.

PubMed Central
OutcomeCancer-Free / NED